Huntsman stock surges 63% after Fair Value spotted opportunity By Investing.com

Huntsman delivered a 62.68% gain in just over five months after InvestingPro flagged it as undervalued (entry $8.12 on Oct 11, 2025 vs InvestingPro intrinsic $12.01, 47.9% upside); shares peaked at $13.21 and trade at $12.66 as of Mar 29, 2026, with InvestingPro’s updated fair value $14.99 implying ~13.5% upside. Company fundamentals show revenue modestly down from $5.78B to $5.68B and EBITDA fell from $310M to $264M, while EPS improved from -$1.91 to -$1.65; Huntsman maintained its dividend and appointed new leadership despite credit downgrades and a Rotterdam outage.

Analysis

Specialty-chem exposure that leans on differentiated product mix (versus commodity-grade output) is the key structural winner here; margins respond asymmetrically to modest demand improvement because pricing power and contract levers are stickier for specialty grades. The second-order beneficiaries are toll-manufacturers, formulators and high-value downstream converters (automotive suppliers, coatings formulators) who face less input-price pass-through volatility and can re-price on multi-quarter contracts. Conversely, pure commodity chemical producers and distributors are at risk of margin compression if feedstock volatility returns or if inventory destocking accelerates across OEM supply chains.

Near-term tradeable catalysts are operational reliability at key capacity points, quarterly commentary on product mix/pricing, and any visible cash-flow improvement that compresses credit spreads; these move sentiment within days-to-weeks. Medium-term (3–12 months) upside requires sustained demand recovery in cyclical end markets and demonstrable FCF conversion that enables net-debt paydown or share-repurchase optionality. Tail risks include sudden spikes in naphtha/propane/ethylene prices, broad-based demand shock (inventory correction), or refinancing stress that forces asset sales—each can reverse the rerating quickly.

Practical execution should isolate mix/margin uplift from broad commodity beta: structural long exposure with hedges or a pair that shorts commodity-levered peers accomplishes this. Options can buy time on a multi-quarter recovery while capping downside. Monitor three high-signal indicators: normalized utilization rates across core plants, sequential gross-margin stabilization by product family, and 3–6 month trajectory of credit spreads relative to IG industrials.

The consensus risk is two-fold: many investors either extrapolate a single beat into structural improvement or discount the rally as purely sentiment-driven. We believe the move is not purely one or the other — upside is real if operational reliability holds, but it is also fragile to input shocks; therefore, sizing and hedge design are decisive for expected returns.

Key Decisions for Investors

• Initiate a 3–5% portfolio weight long HUN (6–12 month horizon). Target +20–30% upside; hard stop at -10–12%. Risk-manage by buying 6‑month puts equal to ~30% notional (protects largest tail risk while keeping upside).
• Pair trade: long HUN / short LYB (or another commodity-heavy chemical peer) dollar-neutral, 3–6 month horizon. Objective is relative outperformance of +12–18% if specialty mix re-prices; risk is broad sector rally where both move up — cap pair size to 1–2% net portfolio exposure.
• Buy a directional call spread on HUN (9‑month): long call at ~+15% and short call at ~+45% (percentages vs current spot). This caps premium outlay while offering 3:1+ upside if recovery sticks; max loss = premium.
• Reallocate momentum exposure: trim 30–50% of SMCI/APP position sizes to fund HUN trades (3-month re-evaluation). Rationale: rotate realized momentum gains into higher idiosyncratic value with hedgeable downside; monitor opportunity cost if tech rally continues and set re-entry triggers.